Breast cancer, blindness and melatonin

Print
Published on Thursday, 02 March 2017

Abstract

The hypothesis is advanced that blindness from an early age may lead to a reduced risk of breast cancer through altered patterns of melatonin secretion by the pineal gland.

The available experimental evidence in animals and in vitro is consistent with this hypothesis.

The hypothesis can be tested in humans by a simple observational study in which the breast cancer risk in blind women is compared with that of all women.

The effect of age at onset, duration and degree of blindness could also be assessed, after adjustment for known risk factors for breast cancer.

Melatonin might prove to be a natural oncostatic agent of practical value in cancer prevention.

 

 

About this publication.

 

See also:

- About Melatonin;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;